Abstract:
This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.
Abstract:
A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Abstract:
A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.
Abstract:
A waste heat recovery system connects a working fluid into passages formed within an internal combustion engine. The fluid passages transport the working fluid to high temperature areas of the engine, raising the temperature of the working fluid near the phase change point or above the phase change point. The heated working fluid drives an energy conversion portion located downstream from the engine. The heat absorbed by the working fluid decreases the load on an engine cooling system as well as driving an energy conversion portion, improving fuel efficiency.
Abstract:
The present invention provides methods and compositions for slowing the transit time of foodstuffs, pharmaceutical compounds, nutritional supplements, and vitamins through the gastrointestinal tract using cyclic Gulp (cGMP) alone and cGMP in combination with succinate. The method and corresponding compositions prolong residence time of such compounds, and thereby increase absorption through the small intestine, increase bioavailability, and improve feed conversion ratios.
Abstract:
One embodiment of the present Invention is a unique vehicle having a hybrid drive system. Other embodiments include unique hybrid drive systems, Still other embodiments include apparatuses, systems, devices, hardware, methods, and combinations for fluid driven actuation systems. Further embodiments, forms, features, aspects, benefits, and advantages of the present application shall become apparent from the description and figures provided herewith.
Abstract:
The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands.
Abstract:
A variable valve actuation system is disclosed, in one form a rocker is disclosed coupled with a valve stem at one end and a cam follower at the other end. The rocker is operable to pivot about a fixed axis. The cam follower is operable to be pivotally coupled with the rocker at one end of the cam follower. The cam follower includes a lower roller and an upper roller at its other end, each operable to engage cam lobes on separate cam shafts. In one form the cam follower includes a lower roller operable to follow a cam lobe on a lower cam shaft and an upper roller operable to follow a cam lobe on an upper cam shaft. The upper cam shaft and the lower cam shaft can have variable lobes. A spring can be used to bias the cam follower on the rocker.
Abstract:
This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)
Abstract:
A valve train assembly (16) includes a fuel injector (1), an intake rocker lever assembly (10), and an exhaust rocker lever assembly (14). The intake and exhaust rocker lever assemblies (10) can include an eccentric hydraulic lash adjuster (11) that is located in the nose (31) of the respective rocker lever assemblies (10). The rocker lever assemblies (10) are configured to allow a clearance area between a nose (31) of the intake rocker lever assembly (10) and the nose (31) of the exhaust rocker lever assembly (14). As such, the fuel injector (1) can be positioned in the clearance area, while still allowing the eccentric hydraulic lash adjusters to apply a load onto a corresponding valve bridge (2). For example, the eccentric hydraulic lash adjuster (11) can include an outer housing (20) and a pivot ball (21), wherein the pivot ball (21) is positioned at an offset (23) from a lateral centerline of the outer housing (20).